← Eichor
Condition: Diffuse Astrocytoma Idh Mutant Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Diffuse Astrocytoma Idh Mutant

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of 177Lu-PSMA-617 in People With Gliomas
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07223034Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT07468136PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
NA · 1 location(s) · Oslo University Hospital · NCT05190172Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · 43 location(s) · National Cancer Institute (NCI) · NCT06860594Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/Phase 2 · 7 location(s) · Neonc Technologies, Inc. · NCT06047379
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.